Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants

NCT ID: NCT07117669

Last Updated: 2025-08-21

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 68 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-31
• Study Completion Date: 2028-11-30

Brief Summary

This is a Phase 1/2 study to evaluate the safety and clinical activity of ENP-501 in non-peanut allergic (NPA) healthy participants and participants with an established peanut allergy (PA)

Conditions

Peanut Allergy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ENP-501

Group Type: EXPERIMENTAL

ENP-501

Intervention Type: DRUG

• Part 1: Participants will receive buccal administrations of ENP-501 daily for 6-14 weeks
• Part 2: Participants will receive buccal administrations of ENP-501 daily for 52 weeks following achieving the 2000 µg target dose

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

• Part 1: Participants will receive buccal administrations of placebo daily for 6-14 weeks
• Part 2: Participants will receive buccal administrations of placebo daily for 52 weeks following achieving the 2000 µg target dose

Interventions

ENP-501

• Part 1: Participants will receive buccal administrations of ENP-501 daily for 6-14 weeks
• Part 2: Participants will receive buccal administrations of ENP-501 daily for 52 weeks following achieving the 2000 µg target dose

Intervention Type: DRUG

Placebo

• Part 1: Participants will receive buccal administrations of placebo daily for 6-14 weeks
• Part 2: Participants will receive buccal administrations of placebo daily for 52 weeks following achieving the 2000 µg target dose

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Part 1:

• 14-50 years of age (inclusive)
• Otherwise medically healthy and able to participate in the study
• Able to perform spirometry testing in accordance with the American Thoracic Society (ATS) guidelines (2019)
• All women of child-bearing potential, agree to either abstain from sexual activity or agree to use an adequate method of contraception for the duration of the study and for 30 days after the last dose of investigational product
• Signed and dated written informed consent from the participant and/or parent or guardian
• Signed and dated assent from participant under 18 in accordance with local IRB regulations
• Willing and able to avoid peanut and peanut contaminants for the duration of the trial

Part 1 Cohort 1 only (NPA Participants)

• No known clinical history of peanut allergy with regular exposure to peanuts in daily life, i.e ingests peanuts without symptoms
• Negative Skin Prick Test (SPT) (wheal diameter of <3 mm) to peanut

Part 1 Cohort 2 only (PA Participants)

• A documented clinical history of peanut allergy, which includes the development of symptoms (e.g., urticaria, flushing, rhinorrhea and sneezing, throat tightness or hoarseness, wheezing, vomiting) verified by a physician
• At least two of the three following requirements:

1. Positive Skin Prick Test (SPT) (wheal diameter of ≥ 8 mm) to peanut

2. An elevated serum peanut specific IgE level ≥ 7 kUA/L (ImmunoCAP®)

3. An Ara-h2 IgE level of ≥ 2 kUA/L (ImmunoCAP®)

Part 2:

• 14 to 50 years of age (inclusive)
• A documented clinical history of peanut allergy, which includes the development of symptoms (e.g., urticaria, flushing, rhinorrhea and sneezing, throat tightness or hoarseness, wheezing, vomiting) verified by a physician
• At least two of the three following requirements at screening:

1. Positive SPT (wheal diameter of ≥ 3 mm) to peanut

2. Serum peanut-specific IgE level ≥ 0.7 kUA/L (ImmunoCAP®)

3. An Ara-h2 IgE level of ≥ 0.5 kUA/L (ImmunoCAP®) within 1 year of enrollment

• Participant must be willing and able to complete a DBPCFC at screening and EOT (24-hours after last dose) and experience dose-limiting symptoms at or before the 300 mg challenge dose of peanut protein during a Double Blind, Placebo Controlled Food Challenge (DBPCFC) conducted in accordance with Practical Issues in Allergology, Joint United States/European Union Initiative (PRACTALL) guidelines
• Otherwise medically healthy and able to participate in the study
• Able to perform spirometry testing in accordance with the ATS guidelines (2019)
• All women of child-bearing potential, agree to either abstain from sexual activity or agree to use an adequate method of contraception for the duration of the study and for 30 days after the last dose of investigational product
• Signed and dated written informed consent from the participant and/or parent or guardian
• Signed and dated assent from participant under 18 in accordance with local IRB regulations
• Willing and able to avoid peanut and peanut contaminants for the duration of the trial

Exclusion Criteria

• History of severe anaphylactic event requiring mechanical ventilation or use of intravenous (IV) vasopressor drugs
• Clinically significant screening electrocardiogram (ECG) abnormality or corrected QTcF >/= 450 msec at Screening
• FEV1 value < 80% predicted at Screening
• Any hospitalization in the past year for asthma, >1 course of oral steroids for asthma in the past 6 months, or any emergency room visit in the past 6 months for asthma
• Poorly controlled atopic dermatitis
• Eosinophilic gastrointestinal disease
• Use of oral or IV corticosteroids within 30 days of Screening
• Use of tricyclic antidepressants within 6 months of Screening
• Inability to discontinue antihistamines for at least 5 half-lives before skin testing
• Use of omalizumab or other immunomodulatory therapy (not including corticosteroids) or biologic therapy within one year of Screening
• Use of any food allergen-specific or other non-traditional form of allergen immunotherapy within one year of Screening
• Use of immunosuppressive drugs within 30 days of Screening
• Use of ß-blockers (oral)
• Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, and/or laboratory studies including urinalysis
• Pregnant or breast-feeding (if female)
• Behavioral, cognitive, or psychiatric disease that in the opinion of the Investigator affects the ability of the participant to understand and cooperate with the study protocol
• Known allergy to inactive ingredients of investigational product (active or placebo)
• Participation in another interventional clinical trial within 30 days of Screening or within 5 half-lives of the other IP
• Residing at the same address as another participant in this or any peanut immunotherapy study

• Minimum Eligible Age: 14 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

CBCC Global Research

NETWORK

Sponsor Role: collaborator

N-Fold, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Research Site 001

Aurora, Colorado, United States

Countries

United States

Central Contacts

Balraj Sangha

Role: CONTACT

balraj.sangha@cbcc.global

+1 (661) 322-2206

Other Identifiers

ENP-501-001

Identifier Type: -

Identifier Source: org_study_id